echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > J Hepatol: Maddrey scored 32 and pathologically suggested long-term prognosis in patients with alcoholic liver disease with fatty hepatitis.

    J Hepatol: Maddrey scored 32 and pathologically suggested long-term prognosis in patients with alcoholic liver disease with fatty hepatitis.

    • Last Update: 2020-08-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Patients with alcoholic hepatitis had a lower short-term mortality rate when the Maddrey (mDF) differentiation function was improved.
    but there is little data on long-term prognostics in such patients.
    study was conducted to assess the 5-year survival rate of patients with Madrey's 32-point alcohol hepatitis and to identify predictive factors that affect long-term prognosis.
    the study was a retrospective study conducted at two medical centres in Belgium and Austria.
    included in 2 medical centers in the past due to the loss of compensation period liver disease admitted patients, patients of missing compensation period liver disease is manifested in the presence of ase abdominal water, liver encephalopathy or jaundice, all patients have received liver puncture biopsy, histology performance is fatty hepatitis, mDF -lt;32 points.
    to record clinical and biological parameters during liver biopsies and information on the amount of alcohol consumed by patients during follow-up.
    data is used for Cox risk scale regression models and survival analyses to determine factors associated with the 5-year survival rate.
    121 patients, 64% were men, with an average age of 51.5 to 10.3 years, and 84% were patients with cirrhosis.
    of the end-stage liver disease model and Madrey score were 14 (IQR 11.7 to 16.1) and 19 (IQR 11.1 to 24), respectively.
    about 30 percent of patients absted from alcohol during follow-up.
    1st, 6th, 12th, 24th and 60th months survival rates were 96.7 to 1.6%, 90.1 to 2.7%, 80.8 to 3.6%, 69.9 to 4.3% and 50.7 to 4.9%, respectively.
    most patients die from liver-related diseases (80%).
    multivariable analysis, baseline examination of patients for encephalopathy and alcohol withdrawal was a factor in predicting a patient's 5-year survival rate.
    The 5-year survival rates of patients without hepatic encephalopathy and liver encephalopathy were 60.5 to 5.8% and 29.7 to 8.0%, respectively, and the five-year survival rates of patients who abstedred from alcohol and non-alcoholic diseases were 74.0 to 8.0% and 40.9 to 5.8%, respectively.
    study showed that the five-year mortality rate for patients with alcohol-related hepatitis at Maddrey's 32 points was about 50 percent.
    long-term prognosis in patients with hepatic encephalopathy and non-alcohol withdrawal at the baseline.
    for this type of patient, new treatment strategies such as guiding patients to strictly abstned from alcohol should be considered during treatment.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.